100% Secure Payments
Tender Details
- Country: United Kingdom
- Summary: Services to Deliver Onasemnogene Abeparvovec/Zolgensma
- GBT Ref No: 49809922
- Deadline: 08 Mar 2021
- Competition: ICB
- Financier: Self Financed
- Purchaser Ownership: -
- Tender Value: 6000000
- Notice Type: Tender
- Document Ref. No.:
- Purchaser's Detail :
- Description :
- Title : Services to deliver Onasemnogene abeparvovec/Zolgensma
Location Of Contract : Any region
Industry : Health and social work services - 85000000 Health services - 85100000 Miscellaneous health services - 85140000
Value Of Contract : £2,500,000 to £6,000,000
Description : Spinal muscular atrophy, or SMA, is a rare genetic disorder that causesmuscle weakness and progressive loss of movement. It is most commonlycaused by defects in the gene SMN1.Onasemnogene abeparvovec (Zolgensma, AveXis) is a single-use gene replacement therapy made of a viral vector that has been modified to contain the primary gene for the human survival motor neuron (SMN) protein, which islacking or mutated in people with SMA. When injected, the vector is expectedto carry the gene into the nerve cells, enabling production of sufficientamounts of SMN. It is administered intravenously.NHS England is seeking to commission a service to deliver Onasemnogene abeparvovec/Zolgensma from four providers in England. It is currently anticipated that there may be one provider to cover the North of England, one to cover the Midlands, one to cover the South of England plus one other. The commissioner is by no means fixed on this geographical spread as the quality of the service provision is the most important factor. As well as having a neuromuscular MDT and experience in treating children with SMA, the s... - Documents :
Purchaser : NHS ARDEN AND GREATER EAST MIDLANDS COMMISSIONING SUPPORT UNIT
80 London Road London SE1 6LH ENG
Contact Person : Anna Salt
Email :anna.salt@nhs.net
If you are registered member, kindly login to view full details of this tender notice:
CLICK HERE TO LOGIN
